Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04275947Unknown

The COVID-19 Mobile Health Study (CMHS)

Role: lead

NCT03882684Unknown

Role of Genomic Imprinting in Cancer Diagnosis

Role: lead

NCT02693496Unknown

Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research

Role: lead

NCT02726633Unknown

Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer

Role: lead

All 4 trials loaded